Navigation Links
Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
Date:12/10/2013

rease, and glutaminase inhibition.   Efficacious doses of CB-839 were well tolerated with no effects on hematologic cell counts or body weight.  The strong correlation between glutamine dependence and sensitivity to CB-839 in B cell tumor lines suggests that glutamine supports cell growth and survival in these tumors through metabolism of glutamine by glutaminase.  Calithera plans to advance CB-839 into Phase 1 clinical trials in patients with advanced solid and hematological tumors in early 2014.  

Calithera's in vitro and in vivo data on CB-839 were presented in a poster entitled, "Antitumor Activity of the Glutaminase Inhibitor CB-839 in Hematological Malignancies," (Abstract #4226), during the Chemical Biology and Experimental Therapeutics on December 9, 2013.

About Calithera Biosciences
Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival.  The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development.  The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics.  Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing.  Calithera Biosciences is a privately held company located in South San Francisco, CA.  For more information, please visit www.calithera.com.


'/>"/>
SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
2. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
3. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
4. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
5. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
6. Telomere Biosciences Announces: TELO-100 with T-Activator 150, a Breakthrough in Telomere Science and Age Management
7. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
8. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
9. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
10. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
11. Ambit Biosciences Announces Third Quarter 2013 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology,  today celebrated continued ... its exVive3D TM Human Liver Tissue.  The ... commercial release on November 18, has been recognized ... awards for innovation. Most recently, on ...
(Date:12/15/2014)... Limited (NASDAQ GS: SEED) (" Origin ", or the " ... China , today announced that the Company will ... 2014, before the market opens on Thursday, January 8, 2015. ... 8, 2015, at 8:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial +1-888-346-8982 in ...
(Date:12/13/2014)... 2014 CanDiag, Inc., a University of ... changed its name to OncoTab, Inc. , “The ... we are today,” said CEO and Chief Science Officer, ... beyond breast cancer diagnostics to include imaging and therapies, ... evolution.” , Founded in 2011 by Dr. Mukherjee, an ...
(Date:12/13/2014)... 2014 Clarassance, a privately held clinical-stage ... name: Therabron Therapeutics , Inc. The new name ... type of structure in the lungs similar to branches ... develop novel protein therapeutics for the treatment of respiratory ... change the name to mark the company's escalation into ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... VRUS ) management will present at the Morgan ... 2008 to May 2,2008 at the Ritz-Carlton Key Biscayne ... provide an overview of the,company and participate in a ... 2008 at 3:40 PM (ET) in the Plaza,Ballroom., ...
... AANS/CNS Section on Tumors,and BrainLAB today announced the ... MD, from the People,s Republic of China, was,awarded ... Bone Marrow,Derived Mesenchymal Stem Cells in Brain Tumor ... a $50,000 stipend to conduct research in his,proposed ...
... 24 The Board of,Directors of Shire plc ... specialty,biopharmaceutical company, announces today that Michael Rosenblatt M.D.,will ... immediate effect., Dr Rosenblatt is the Dean ... was previously Professor of Medicine at Harvard,Medical School ...
Cached Biology Technology:Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th 2AANS/CNS and BrainLAB Announce Winner of 2008 International Research Fellowship 2AANS/CNS and BrainLAB Announce Winner of 2008 International Research Fellowship 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 4
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... international team of researchers led by Daniel J. ... for Translational Medicine and Therapeutics, has received a ... to study the molecular genetics of atherosclerotic cardiovascular ... Genes Associated with Plasma Lipids and Cardiovascular Disease," ...
... A cat regularly vomiting hairballs or refusing to eat probably ... might say. There is a good chance that the cat ... in its environment, new research suggests. Healthy cats were ... vomit frequently and leave waste outside their litter box in ...
... engineering faculty at Oregon State University have invented a ... will be particularly useful for cleanup of sites with ... less expensive. A patent has been granted on ... production of devices will begin soon. The advance has ...
Cached Biology News:Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Even healthy cats act sick when their routine is disrupted 2Even healthy cats act sick when their routine is disrupted 3Even healthy cats act sick when their routine is disrupted 4Even healthy cats act sick when their routine is disrupted 5New technology to speed cleanup of nuclear contaminated sites 2